Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
NOVN.SW
Home
/
NOVN.SW

SIX
CHF134.26
CHF134.26

Overview

Price performance
Low
CHF 130.70
High
CHF 134.26
Market closed. Last updated: Nov 4, 2026, 4:31 PM UTC
CHF 
134.26
2.76 (2.10%)
Average, 50 days
CHF 122.12
CHF 121.70
Open
CHF 131.36
Previous close
CHF 131.50
52-week high
CHF 135.06
Oct 30, 2026 (6 days ago)
52-week low
CHF 99.45
Nov 21, 2025 (1 year ago)
35.00%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
253.57B
Volume
3 843 807
Total Return (3M)
7.75%
Total Return (1Y)
32.30%
10.57
Sector
Healthcare
Links
Tags
Healthcare
Drug Manufacturers - General
SIX
CH
Website
novartis.com
About
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Frequently asked questions

NOVN.SW · Novartis AG

01What is Novartis AG stock price today?

The current price of NOVN.SW is CHF 134.26 — it has increased by 2.10% since the previous close. Data as of Nov 4, 2026.

02Is Novartis AG stock price growing?

NOVN.SW is down 0.18% over the past week, up 15.40% over the past month and up 32.30% over the past year. The price is above its 200-day moving average of CHF 121.70.

03What is Novartis AG market cap?

Novartis AG has a market capitalization of CHF 253.57B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

04How volatile is NOVN.SW stock?

In the latest trading session NOVN.SW moved between CHF 130.70 and CHF 134.26, a range of 2.65% of its current price.

05What are NOVN.SW stock 52-week high and low?

Over the past 52 weeks NOVN.SW has traded between CHF 99.45 and CHF 135.06. The current price is 0.59% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.